Cansino Biologics Inc (688185) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.006x

Based on the latest financial reports, Cansino Biologics Inc (688185) has a cash flow conversion efficiency ratio of 0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥30.53 Million ≈ $4.47 Million USD) by net assets (CN¥4.93 Billion ≈ $721.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cansino Biologics Inc market cap and net worth for the company's overall valuation and market capitalisation.

Cansino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Cansino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cansino Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cansino Biologics Inc ranked by their cash flow conversion efficiency. Explore Cansino Biologics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Cronos Group Inc TO:CRON	0.012x
TianJin 712 Communication & Broadcasting Co Ltd SHG:603712	-0.055x
Dongguan Eontec Co Ltd SHE:300328	-0.047x
Radiant Opto-Electronics Corp TW:6176	-0.005x
Ziel Home Furnishing Technology Co. Ltd. A SHE:301376	N/A
North Huajin Chemical Industries Co Ltd SHE:000059	-0.070x
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	0.003x
Globant S.A. LSE:0RIX	N/A

Annual Cash Flow Conversion Efficiency for Cansino Biologics Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of Cansino Biologics Inc from 2016 to 2025. View 688185 stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥12.11 Billion ≈ $1.77 Billion	CN¥77.86 Million ≈ $11.39 Million	0.006x	+118.72%
2024-12-31	CN¥4.92 Billion ≈ $719.24 Million	CN¥-168.79 Million ≈ $-24.70 Million	-0.034x	+80.18%
2023-12-31	CN¥5.29 Billion ≈ $773.72 Million	CN¥-916.25 Million ≈ $-134.08 Million	-0.173x	+33.48%
2022-12-31	CN¥7.25 Billion ≈ $1.06 Billion	CN¥-1.89 Billion ≈ $-276.22 Million	-0.261x	-210.54%
2021-12-31	CN¥8.55 Billion ≈ $1.25 Billion	CN¥2.01 Billion ≈ $294.79 Million	0.236x	+404.82%
2020-12-31	CN¥6.07 Billion ≈ $888.36 Million	CN¥-469.39 Million ≈ $-68.69 Million	-0.077x	+33.19%
2019-12-31	CN¥1.47 Billion ≈ $215.18 Million	CN¥-170.19 Million ≈ $-24.90 Million	-0.116x	+52.98%
2018-12-31	CN¥502.32 Million ≈ $73.50 Million	CN¥-123.64 Million ≈ $-18.09 Million	-0.246x	-165.51%
2017-12-31	CN¥607.33 Million ≈ $88.87 Million	CN¥-56.30 Million ≈ $-8.24 Million	-0.093x	+42.17%
2016-12-31	CN¥214.47 Million ≈ $31.38 Million	CN¥-34.38 Million ≈ $-5.03 Million	-0.160x	--

About Cansino Biologics Inc

SHG:688185 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.33 Billion

CN¥9.12 Billion CNY

Market Cap Rank

#7777 Global

#1754 in China

Share Price

CN¥79.74

Change (1 day)

+10.05%

52-Week Range

CN¥47.90 - CN¥92.78

All Time High

CN¥773.75